GlassScriptPhysician profile
David Mandelblum
NPI 1093807752
$2,235.34
in general payments reported to CMS, 2019-2025
28 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $24.63 · 2021: $211 · 2022: $295 · 2023: $323 · 2024: $752 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $298.77 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $250.00 | 2022 | |
| Exact Sciences Corporation | $239.09 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $220.92 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $211.19 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $182.83 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $106.65 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Sonex Health, INC. | $86.95 | 2024 | Sx-One Microknife |
| Abbvie INC. | $75.02 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $60.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.21 | 2021-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.59 | 2019 | |
| Dexcom, INC. | $41.47 | 2024 | Dexcom G6 Transmitter |
| Phadia US INC. | $38.85 | 2024 | Immunocap |
| Amarin Pharma, INC. | $37.35 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $32.35 | 2019 | |
| Novo Nordisk INC | $28.68 | 2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $27.41 | 2024 | |
| Kvk-Tech, INC. | $24.63 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.27 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.12 | 2024 | Oxlumo |
| Novartis Pharmaceuticals Corporation | $21.32 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.22 | 2023 | |
| Biogen, INC. | $18.52 | 2021 | |
| Hologic Sales and Service, LLC | $15.84 | 2019 | |
| Alkermes, INC. | $15.67 | 2019 | |
| Insmed, INC. | $15.13 | 2025 | Brinsupri, Arikayce |
| Cipher Pharmaceuticals US LLC | $14.29 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mandelblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.